For research use only. Not for therapeutic Use.
Dinutuximab(CAT: I040743) is a chimeric monoclonal antibody (IgG1) that targets GD2, a disialoganglioside highly expressed on the surface of neuroblastoma and other neuroectodermal tumors. By binding to GD2, Dinutuximab induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), promoting immune-mediated tumor cell destruction. It is FDA-approved for the treatment of high-risk pediatric neuroblastoma in combination with cytokines and retinoids. Dinutuximab is also a key agent in immuno-oncology research, particularly in studies of GD2-targeted therapies, neuroblastoma biology, and tumor immune evasion.
| CAS Number | 1363687-32-4 |
| Purity | ≥95% |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
